News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Release: Study Showed VYTORIN Superior To Lipitor At Lowering LDL Cholesterol



10/19/2005 5:12:56 PM

Results from a clinical trial conducted in 1,902 patients with high cholesterol showed that VYTORIN(TM) (ezetimibe/simvastatin) provided greater reduction in LDL ("bad") cholesterol across the dosing ranges compared to Lipitor. At the most commonly used starting doses of these two therapies, VYTORIN 10/20 mg decreased LDL cholesterol by 51 percent compared with 36 percent for Lipitor 10 mg (p<0.001). The results were presented today at the American College of Cardiology's 2005 Annual Scientific Session.

Read at Reuters
Read at HealthDay
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES